世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
Biologics Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global biologics contract manufacturing market is set for remarkable growth, with worldwide revenue anticipated to increase from USD 16.01 billion in 2024 to an impressive USD 36.3 billion by 2... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global biologics contract manufacturing market is set for remarkable growth, with worldwide revenue anticipated to increase from USD 16.01 billion in 2024 to an impressive USD 36.3 billion by 2031. Projected to grow at a CAGR of 12.4%, this surge reflects heightened demand for innovative biologic and biosimilar products, as companies increasingly leverage contract manufacturing to streamline R&D and commercialization.The biologics contract manufacturing market's expansion is fueled by the growth of the biopharmaceutical contract manufacturing organization (CMO) sector. Industry players are focusing on consolidation, adopting inorganic growth strategies, and developing integrated end-to-end solutions to offer comprehensive services. Biopharmaceutical CMOs with advanced technological capabilities are well-positioned to capitalize on this expanding market, driven by rapid scientific advancements in the field. Drivers of Market Growth 1.Growing Demand for Biologics and Biosimilars: Rising demand for biologics and biosimilars is driving contract manufacturing services growth. 2.R&D Outsourcing: Companies are increasingly outsourcing R&D to CMOs and CDMOs (contract development and manufacturing organizations) to reduce costs and improve operational efficiency. 3.Scientific and Technological Advancements: Innovations like single-use bioreactors and cell & gene therapy capabilities are bolstering market growth. For instance, Lonza Group AG's acquisition of Shire plc’s facility expanded mammalian manufacturing operations, and AGC Biologics’ acquisition of Molecular Medicine S.p.A. strengthened its gene therapy capabilities. Business Opportunities The evolving CDMO business model supports high-potency drug development and biopharmaceuticals, enabling companies to achieve efficiency across the value chain by outsourcing clinical development stages. CMOs and CDMOs optimizing manufacturing technologies are also driving long-term profitability through scalable, cost-effective solutions. Region Analysis •United States: In North America, the U.S. dominates, capturing around 89.9% of the market in 2023. Robust biologics pipelines, substantial venture capital investment in biotechnology R&D, and a strong presence of leading manufacturers bolster its position. •Germany: With 33.7% of Europe’s market share in 2023, Germany emerges as a key market, driven by increased biopharmaceutical research and clinical trials. Companies outsource research activities to reduce costs, further propelling market demand. •China: Commanding an 18.2% market share in East Asia, China benefits from global-local collaborations. The rising presence of pharmaceutical and biopharmaceutical companies in China is unlocking growth opportunities for contract manufacturing. Impact of Regulatory Dynamics The biologics contract manufacturing market faces challenges from evolving regulatory policies, cGMP compliance mandates, and supply chain security complexities in emerging markets. Entry barriers for SMEs are high due to significant financial requirements. Additionally, the biotech industry in many countries lags behind the U.S. due to shortages of skilled professionals and funding. Competitive Analysis Leading players are expanding service portfolios and focusing on emerging markets to harness growth opportunities. Major companies in the biologics contract manufacturing market include: •BioXcellence (Boehringer Ingelheim) •Lonza Group AG •Samsung Biologics •Fujifilm Diosynth Biotechnologies •AbbVie CM (AbbVie Inc.) •WuXi Biologics (Cayman) Inc. •AGC Biologics •Patheon N.V. (Thermo Fisher Scientific Inc.) •Emergent BioSolutions Inc. •Ajinomoto Bio-Pharma •Avid Bioservices, Inc. •KBI Biopharma •Rentschler Biotechnologie GmbH •Merck KGaA •Catalent Inc. •Therapure Biopharma Inc. •Novasep •Abzena plc. •ProBioGen AG Biologics Contract Manufacturing Market Segmentation Product: •Monoclonal Antibodies •Recombinant Proteins •Vaccines •Insulin •Interferons •Growth Factors •Others Platform: •Mammalian •Microbial Therapeutic Area: •Oncology •Autoimmune Disease •Metabolic Disease •Ophthalmology •Cardiovascular Disease •Infectious Disease •Neurology •Respiratory Disorder •Others Application: •Commercial •Clinical Region: •North America •Latin America •Europe •South Asia •East Asia •Oceania •Middle East & Africa Table of Contents1. Executive Summary1.1. Global Biologics Contract Manufacturing Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value and Volume, 2024 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Price Analysis, 2018 – 2023 3.1. Global Average Price Analysis, by Product/ Platform, US$ Per Unit, 2018 – 2023 3.2. Prominent Factor Affecting Biologics Contract Manufacturing Prices 3.3. Global Average Price Analysis, by Region, US$ Per Unit 4. Global Biologics Contract Manufacturing Market Outlook, 2019-2031 4.1. Global Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 4.1.1. Key Highlights 4.1.1.1. Monoclonal Antibodies 4.1.1.2. Recombinant Proteins 4.1.1.3. Vaccines 4.1.1.4. Insulin 4.1.1.5. Interferons 4.1.1.6. Growth Factors 4.1.1.7. Others 4.2. Global Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 4.2.1. Key Highlights 4.2.1.1. Mammalian 4.2.1.2. Microbial 4.3. Global Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 4.3.1. Key Highlights 4.3.1.1. Oncology 4.3.1.2. Autoimmune Disease 4.3.1.3. Metabolic Disease 4.3.1.4. Ophthalmology 4.3.1.5. Cardiovascular Disease 4.3.1.6. Infectious Disease 4.3.1.7. Neurology 4.3.1.8. Respiratory Disorder 4.3.1.9. Others 4.4. Global Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 4.4.1. Key Highlights 4.4.1.1. Commercial 4.4.1.2. Clinical 4.5. Global Biologics Contract Manufacturing Market Outlook, by Region, Value (US$ Bn) and Volume (KL), 2019-2031 4.5.1. Key Highlights 4.5.1.1. North America 4.5.1.2. Europe 4.5.1.3. Asia Pacific 4.5.1.4. Latin America 4.5.1.5. Middle East & Africa 5. North America Biologics Contract Manufacturing Market Outlook, 2019-2031 5.1. North America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 5.1.1. Key Highlights 5.1.1.1. Monoclonal Antibodies 5.1.1.2. Recombinant Proteins 5.1.1.3. Vaccines 5.1.1.4. Insulin 5.1.1.5. Interferons 5.1.1.6. Growth Factors 5.1.1.7. Others 5.2. North America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 5.2.1. Key Highlights 5.2.1.1. Mammalian 5.2.1.2. Microbial 5.3. North America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 5.3.1. Key Highlights 5.3.1.1. Oncology 5.3.1.2. Autoimmune Disease 5.3.1.3. Metabolic Disease 5.3.1.4. Ophthalmology 5.3.1.5. Cardiovascular Disease 5.3.1.6. Infectious Disease 5.3.1.7. Neurology 5.3.1.8. Respiratory Disorder 5.3.1.9. Others 5.4. North America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 5.4.1. Key Highlights 5.4.1.1. Commercial 5.4.1.2. Clinical 5.5. North America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1. Key Highlights 5.5.1.1. U.S. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.2. U.S. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.3. U.S. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.4. U.S. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.5. Canada Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.6. Canada Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.7. Canada Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.1.8. Canada Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 5.5.2. BPS Analysis/Market Attractiveness Analysis 6. Europe Biologics Contract Manufacturing Market Outlook, 2019-2031 6.1. Europe Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.1.1. Key Highlights 6.1.1.1. Monoclonal Antibodies 6.1.1.2. Recombinant Proteins 6.1.1.3. Vaccines 6.1.1.4. Insulin 6.1.1.5. Interferons 6.1.1.6. Growth Factors 6.1.1.7. Others 6.2. Europe Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.2.1. Key Highlights 6.2.1.1. Mammalian 6.2.1.2. Microbial 6.3. Europe Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.3.1. Key Highlights 6.3.1.1. Oncology 6.3.1.2. Autoimmune Disease 6.3.1.3. Metabolic Disease 6.3.1.4. Ophthalmology 6.3.1.5. Cardiovascular Disease 6.3.1.6. Infectious Disease 6.3.1.7. Neurology 6.3.1.8. Respiratory Disorder 6.3.1.9. Others 6.4. Europe Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.4.1. Key Highlights 6.4.1.1. Commercial 6.4.1.2. Clinical 6.5. Europe Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1. Key Highlights 6.5.1.1. Germany Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.2. Germany Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.3. Germany Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.4. Germany Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.5. U.K. Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.6. U.K. Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.7. U.K. Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.8. U.K. Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.9. France Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.10. France Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.11. France Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.12. France Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.13. Italy Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.14. Italy Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.15. Italy Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.16. Italy Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.17. Turkey Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.18. Turkey Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.19. Turkey Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.20. Turkey Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.21. Russia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.22. Russia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.23. Russia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.24. Russia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.25. Rest of Europe Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.26. Rest of Europe Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.27. Rest of Europe Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.1.28. Rest of Europe Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 6.5.2. BPS Analysis/Market Attractiveness Analysis 7. Asia Pacific Biologics Contract Manufacturing Market Outlook, 2019-2031 7.1. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.1.1. Key Highlights 7.1.1.1. Monoclonal Antibodies 7.1.1.2. Recombinant Proteins 7.1.1.3. Vaccines 7.1.1.4. Insulin 7.1.1.5. Interferons 7.1.1.6. Growth Factors 7.1.1.7. Others 7.2. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.2.1. Key Highlights 7.2.1.1. Mammalian 7.2.1.2. Microbial 7.3. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.3.1. Key Highlights 7.3.1.1. Oncology 7.3.1.2. Autoimmune Disease 7.3.1.3. Metabolic Disease 7.3.1.4. Ophthalmology 7.3.1.5. Cardiovascular Disease 7.3.1.6. Infectious Disease 7.3.1.7. Neurology 7.3.1.8. Respiratory Disorder 7.3.1.9. Others 7.4. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.4.1. Key Highlights 7.4.1.1. Commercial 7.4.1.2. Clinical 7.5. Asia Pacific Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1. Key Highlights 7.5.1.1. China Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.2. China Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.3. China Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.4. China Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.5. Japan Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.6. Japan Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.7. Japan Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.8. Japan Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.9. South Korea Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.10. South Korea Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.11. South Korea Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.12. South Korea Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.13. India Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.14. India Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.15. India Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.16. India Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.17. Southeast Asia Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.18. Southeast Asia Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.19. Southeast Asia Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.20. Southeast Asia Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.21. Rest of Asia Pacific Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.22. Rest of Asia Pacific Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.23. Rest of Asia Pacific Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.1.24. Rest of Asia Pacific Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 7.5.2. BPS Analysis/Market Attractiveness Analysis 8. Latin America Biologics Contract Manufacturing Market Outlook, 2019-2031 8.1. Latin America Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 8.1.1. Key Highlights 8.1.1.1. Monoclonal Antibodies 8.1.1.2. Recombinant Proteins 8.1.1.3. Vaccines 8.1.1.4. Insulin 8.1.1.5. Interferons 8.1.1.6. Growth Factors 8.1.1.7. Others 8.2. Latin America Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 8.2.1. Key Highlights 8.2.1.1. Mammalian 8.2.1.2. Microbial 8.3. Latin America Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 8.3.1. Key Highlights 8.3.1.1. Oncology 8.3.1.2. Autoimmune Disease 8.3.1.3. Metabolic Disease 8.3.1.4. Ophthalmology 8.3.1.5. Cardiovascular Disease 8.3.1.6. Infectious Disease 8.3.1.7. Neurology 8.3.1.8. Respiratory Disorder 8.3.1.9. Others 8.4. Latin America Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 8.4.1. Key Highlights 8.4.1.1. Commercial 8.4.1.2. Clinical 8.5. Latin America Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1. Key Highlights 8.5.1.1. Brazil Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.2. Brazil Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.3. Brazil Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.4. Brazil Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.5. Mexico Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.6. Mexico Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.7. Mexico Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.8. Mexico Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.9. Argentina Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.10. Argentina Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.11. Argentina Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.12. Argentina Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.13. Rest of Latin America Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.14. Rest of Latin America Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.15. Rest of Latin America Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.1.16. Rest of Latin America Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 8.5.2. BPS Analysis/Market Attractiveness Analysis 9. Middle East & Africa Biologics Contract Manufacturing Market Outlook, 2019-2031 9.1. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.1.1. Key Highlights 9.1.1.1. Monoclonal Antibodies 9.1.1.2. Recombinant Proteins 9.1.1.3. Vaccines 9.1.1.4. Insulin 9.1.1.5. Interferons 9.1.1.6. Growth Factors 9.1.1.7. Others 9.2. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.2.1. Key Highlights 9.2.1.1. Mammalian 9.2.1.2. Microbial 9.3. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.3.1. Key Highlights 9.3.1.1. Oncology 9.3.1.2. Autoimmune Disease 9.3.1.3. Metabolic Disease 9.3.1.4. Ophthalmology 9.3.1.5. Cardiovascular Disease 9.3.1.6. Infectious Disease 9.3.1.7. Neurology 9.3.1.8. Respiratory Disorder 9.3.1.9. Others 9.4. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.4.1. Key Highlights 9.4.1.1. Commercial 9.4.1.2. Clinical 9.5. Middle East & Africa Biologics Contract Manufacturing Market Outlook, by Country, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1. Key Highlights 9.5.1.1. GCC Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.2. GCC Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.3. GCC Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.4. GCC Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.5. South Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.6. South Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.7. South Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.8. South Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.9. Egypt Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.10. Egypt Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.11. Egypt Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.12. Egypt Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.13. Nigeria Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.14. Nigeria Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.15. Nigeria Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.16. Nigeria Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.17. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Product, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.18. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Platform, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.19. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Therapeutic Area, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.1.20. Rest of Middle East & Africa Biologics Contract Manufacturing Market by Application, Value (US$ Bn) and Volume (KL), 2019-2031 9.5.2. BPS Analysis/Market Attractiveness Analysis 10. Competitive Landscape 10.1. Product vs Platform Heatmap 10.2. Competitive Dashboard 10.3. Company Profiles 10.3.1. BioXcellence (Boehringer Ingelheim) 10.3.1.1. Company Overview 10.3.1.2. Product Portfolio 10.3.1.3. Financial Overview 10.3.1.4. Business Strategies and Development 10.3.2. Lonza Group AG 10.3.2.1. Company Overview 10.3.2.2. Product Portfolio 10.3.2.3. Financial Overview 10.3.2.4. Business Strategies and Development 10.3.3. Samsung Biologics 10.3.3.1. Company Overview 10.3.3.2. Product Portfolio 10.3.3.3. Financial Overview 10.3.3.4. Business Strategies and Development 10.3.4. Fujifilm Diosynth Biotechnologies 10.3.4.1. Company Overview 10.3.4.2. Product Portfolio 10.3.4.3. Financial Overview 10.3.4.4. Business Strategies and Development 10.3.5. AbbVie CM (AbbVie Inc.) 10.3.5.1. Company Overview 10.3.5.2. Product Portfolio 10.3.5.3. Financial Overview 10.3.5.4. Business Strategies and Development 10.3.6. WuXi Biologics (Cayman) Inc. 10.3.6.1. Company Overview 10.3.6.2. Product Portfolio 10.3.6.3. Financial Overview 10.3.6.4. Business Strategies and Development 10.3.7. AGC Biologics 10.3.7.1. Company Overview 10.3.7.2. Product Portfolio 10.3.7.3. Financial Overview 10.3.7.4. Business Strategies and Development 10.3.8. Patheon N.V. (Thermo Fisher Scientific Inc.) 10.3.8.1. Company Overview 10.3.8.2. Product Portfolio 10.3.8.3. Financial Overview 10.3.8.4. Business Strategies and Development 10.3.9. Emergent BioSolutions Inc. 10.3.9.1. Company Overview 10.3.9.2. Product Portfolio 10.3.9.3. Financial Overview 10.3.9.4. Business Strategies and Development 10.3.10. Ajinomoto Bio-Pharma 10.3.10.1. Company Overview 10.3.10.2. Product Portfolio 10.3.10.3. Financial Overview 10.3.10.4. Business Strategies and Development 10.3.11. Avid Bioservices, Inc. 10.3.11.1. Company Overview 10.3.11.2. Product Portfolio 10.3.11.3. Financial Overview 10.3.11.4. Business Strategies and Development 10.3.12. KBI Biopharma 10.3.12.1. Company Overview 10.3.12.2. Product Portfolio 10.3.12.3. Financial Overview 10.3.12.4. Business Strategies and Development 10.3.13. Rentschler Biotechnologie GmbH 10.3.13.1. Company Overview 10.3.13.2. Product Portfolio 10.3.13.3. Financial Overview 10.3.13.4. Business Strategies and Development 10.3.14. Merck KGaA 10.3.14.1. Company Overview 10.3.14.2. Product Portfolio 10.3.14.3. Financial Overview 10.3.14.4. Business Strategies and Development 10.3.15. Catalent Inc. 10.3.15.1. Company Overview 10.3.15.2. Product Portfolio 10.3.15.3. Financial Overview 10.3.15.4. Business Strategies and Development 10.3.16. Therapure Biopharma Inc. 10.3.16.1. Company Overview 10.3.16.2. Product Portfolio 10.3.16.3. Financial Overview 10.3.16.4. Business Strategies and Development 10.3.17. Novasep 10.3.17.1. Company Overview 10.3.17.2. Product Portfolio 10.3.17.3. Financial Overview 10.3.17.4. Business Strategies and Development 10.3.18. Abzena plc. 10.3.18.1. Company Overview 10.3.18.2. Product Portfolio 10.3.18.3. Financial Overview 10.3.18.4. Business Strategies and Development 10.3.19. ProBioGen AG 10.3.19.1. Company Overview 10.3.19.2. Product Portfolio 10.3.19.3. Financial Overview 10.3.19.4. Business Strategies and Development 11. Appendix 11.1. Research Methodology 11.2. Report Assumptions 11.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社のヘルスケアIT分野での最新刊レポート
本レポートと同じKEY WORD（biologics）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/22 10:26 155.52 円 163.34 円 198.56 円 |
